BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 24518094)

  • 21. Intact or broken-apart RNA: an alternative concept for ALK fusion screening in non-small cell lung cancer (NSCLC).
    Kotoula V; Bobos M; Vassilakopoulou M; Tsolaki E; Chrisafi S; Psyrri A; Lazaridis G; Papadopoulou K; Efstratiou I; Michail-Strantzia C; Debelenko LV; Kosmidis P; Fountzilas G
    Appl Immunohistochem Mol Morphol; 2015 Jan; 23(1):60-70. PubMed ID: 25153496
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization.
    Paik JH; Choe G; Kim H; Choe JY; Lee HJ; Lee CT; Lee JS; Jheon S; Chung JH
    J Thorac Oncol; 2011 Mar; 6(3):466-72. PubMed ID: 21258247
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exon scanning by reverse transcriptase-polymerase chain reaction for detection of known and novel EML4-ALK fusion variants in non-small cell lung cancer.
    Sanders HR; Li HR; Bruey JM; Scheerle JA; Meloni-Ehrig AM; Kelly JC; Novick C; Albitar M
    Cancer Genet; 2011 Jan; 204(1):45-52. PubMed ID: 21356191
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
    Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M
    J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma.
    Ying J; Guo L; Qiu T; Shan L; Ling Y; Liu X; Lu N
    Ann Oncol; 2013 Oct; 24(10):2589-2593. PubMed ID: 23904459
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Small non-mucinous bronchioloalveolar carcinoma with anaplastic lymphoma kinase immunoreactivity: a novel ALK fusion gene?
    Yamamoto M; Takeuchi K; Shimoji M; Maniwa T; Isaka M; Nakagawa K; Ohde Y; Kondo H; Nakajima T
    Cancer Sci; 2012 Feb; 103(2):390-2. PubMed ID: 22296236
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers.
    Inamura K; Takeuchi K; Togashi Y; Nomura K; Ninomiya H; Okui M; Satoh Y; Okumura S; Nakagawa K; Soda M; Choi YL; Niki T; Mano H; Ishikawa Y
    J Thorac Oncol; 2008 Jan; 3(1):13-7. PubMed ID: 18166835
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel mass spectrometry-based assay for diagnosis of EML4-ALK-positive non-small cell lung cancer.
    Sakai K; Okamoto I; Takezawa K; Hirashima T; Kaneda H; Takeda M; Matsumoto K; Kimura H; Fujita Y; Nakagawa K; Arao T; Nishio K
    J Thorac Oncol; 2012 May; 7(5):913-8. PubMed ID: 22722791
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH.
    Yi ES; Boland JM; Maleszewski JJ; Roden AC; Oliveira AM; Aubry MC; Erickson-Johnson MR; Caron BL; Li Y; Tang H; Stoddard S; Wampfler J; Kulig K; Yang P
    J Thorac Oncol; 2011 Mar; 6(3):459-65. PubMed ID: 21278610
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chromogenic in situ hybridisation (CISH) is a powerful method to detect ALK-positive non-small cell lung carcinomas.
    Wagner F; Streubel A; Roth A; Stephan-Falkenau S; Mairinger T
    J Clin Pathol; 2014 May; 67(5):403-7. PubMed ID: 24293609
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Custom Gene Capture and Next-Generation Sequencing to Resolve Discordant ALK Status by FISH and IHC in Lung Adenocarcinoma.
    Jang JS; Wang X; Vedell PT; Wen J; Zhang J; Ellison DW; Evans JM; Johnson SH; Yang P; Sukov WR; Oliveira AM; Vasmatzis G; Sun Z; Jen J; Yi ES
    J Thorac Oncol; 2016 Nov; 11(11):1891-1900. PubMed ID: 27343444
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sensitive and affordable diagnostic assay for the quantitative detection of anaplastic lymphoma kinase (ALK) alterations in patients with non-small cell lung cancer.
    Dama E; Tillhon M; Bertalot G; de Santis F; Troglio F; Pessina S; Passaro A; Pece S; de Marinis F; Dell'Orto P; Viale G; Spaggiari L; Di Fiore PP; Bianchi F; Barberis M; Vecchi M
    Oncotarget; 2016 Jun; 7(24):37160-37176. PubMed ID: 27206799
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of novel ALK rearrangement A2M-ALK in a neonate with fetal lung interstitial tumor.
    Onoda T; Kanno M; Sato H; Takahashi N; Izumino H; Ohta H; Emura T; Katoh H; Ohizumi H; Ohtake H; Asao H; Dehner LP; Hill AD; Hayasaka K; Mitsui T
    Genes Chromosomes Cancer; 2014 Oct; 53(10):865-74. PubMed ID: 24965693
    [TBL] [Abstract][Full Text] [Related]  

  • 34. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer.
    Takeuchi K; Choi YL; Togashi Y; Soda M; Hatano S; Inamura K; Takada S; Ueno T; Yamashita Y; Satoh Y; Okumura S; Nakagawa K; Ishikawa Y; Mano H
    Clin Cancer Res; 2009 May; 15(9):3143-9. PubMed ID: 19383809
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer.
    Solomon B; Varella-Garcia M; Camidge DR
    J Thorac Oncol; 2009 Dec; 4(12):1450-4. PubMed ID: 20009909
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ALK status testing in non-small-cell lung carcinoma by FISH on ThinPrep slides with cytology material.
    Minca EC; Lanigan CP; Reynolds JP; Wang Z; Ma PC; Cicenia J; Almeida FA; Pennell NA; Tubbs RR
    J Thorac Oncol; 2014 Apr; 9(4):464-8. PubMed ID: 24736067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiplexed gene expression and fusion transcript analysis to detect ALK fusions in lung cancer.
    Lira ME; Kim TM; Huang D; Deng S; Koh Y; Jang B; Go H; Lee SH; Chung DH; Kim WH; Schoenmakers EF; Choi YL; Park K; Ahn JS; Sun JM; Ahn MJ; Kim DW; Mao M
    J Mol Diagn; 2013 Jan; 15(1):51-61. PubMed ID: 23246132
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TaqMan based real time PCR assay targeting EML4-ALK fusion transcripts in NSCLC.
    Robesova B; Bajerova M; Liskova K; Skrickova J; Tomiskova M; Pospisilova S; Mayer J; Dvorakova D
    Lung Cancer; 2014 Jul; 85(1):25-30. PubMed ID: 24792336
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synergistic Activation upon MET and ALK Coamplification Sustains Targeted Therapy in Sarcomatoid Carcinoma, a Deadly Subtype of Lung Cancer.
    Pelosi G; Gasparini P; Conte D; Fabbri A; Perrone F; Tamborini E; Pupa SM; Ciravolo V; Caserini R; Rossi G; Cavazza A; Papotti M; Nakatani Y; Maisonneuve P; Pastorino U; Sozzi G
    J Thorac Oncol; 2016 May; 11(5):718-728. PubMed ID: 26804638
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
    Toyokawa G; Seto T
    Respir Investig; 2014 Nov; 52(6):330-8. PubMed ID: 25453376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.